Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

January 29, 2020

Primary Completion Date

May 10, 2023

Study Completion Date

June 30, 2025

Conditions
Mature B-cell Malignancies
Interventions
DRUG

Zanubrutinib

Zanubrutinib at 160 mg orally twice daily

Trial Locations (14)

466-8560

Nagoya University Hospital, Nagoya

441-8570

Toyohashi Municipal Hospital, Toyohashishi

260-8717

Chiba Cancer Center, Chiba

790 8524

Matsuyama Red Cross Hospital, Matsuyama

830-0011

Kurume University Hospital, KurumeShi

003-0804

National Hospital Organization Hokkaido Cancer Center, Sapporo

064-0804

Aiiku Hospital, Sapporo

650-0047

Kobe City Medical Center General Hospital, KobeShi

241-8515

Kanagawa Cancer Center, Yokohama

104-0045

National Cancer Center Hospital, ChuoKu

030-8553

Aomori Prefectural Central Hospital, Aomori

500-8513

Gifu Municipal Hospital, Gifu

852-8511

The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki

701-1192

National Hospital Organization Okayama Medical Center, Okayama

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY